
Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study
O'Shaughnessy, J., Sousa, S., Cruz, J., Fallowfield, L., Auvinen, P., Pulido, C., Cvetanovic, A., Wilks, S., Ribeiro, L., Burotto, M., Klingbiel, D., Messeri, D., Alexandrou, A., Trask, P., FredrikssoVolume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.287
Date:
September, 2020
Fichier:
PDF, 102 KB
2020